Clinical Combinations: Dual RAF-MEK Inhibitor & FAK for Treatment of KRAS Mutant Cancers With a Focus Low Grade Ovarian Cancer

Time: 3:35 pm
day: Day Two


• Discuss preclinical rationale for the combination of a dual RAF-MEK and FAK inhibitor
• Outline Phase I study including tolerability, pharmacokinetics an pharmacodynamics
• Consider the clinical efficacy in low grade serious ovarian cancer and comparison with other existing therapies